This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Alzheimer Disease  • Dementias  • Neurology, Other  • Radiologic Imaging  • PET/ SPECT Imaging  • Alert me on articles by topic  Social Bookmarking   What's this?

William E. Klunk, MD, PhD

Arch Neurol. 2008;65(10):1281-1283.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Amyloid imaging with the positron emission tomography (PET) ligand Pittsburgh Compound B (PiB) has spread to many centers around the world since the presentation of its first human studies performed in Uppsala, Sweden, in 2002.¹ At the time of this writing, there are at least 17 sites in North America, 9 in Japan, 8 in Europe, 3 in Korea, and 1 in Australia that have successfully used PiB PET in thousands of subjects. Amyloid imaging with PiB has become an integral part of the Alzheimer's Disease Neuroimaging Initiative in North America and equivalent studies in Japan and Australia. The relatively rapid worldwide acceptance of this new technology lies partly in the potential utility of amyloid imaging for the following: (1) early (perhaps presymptomatic) diagnosis; (2) the development of antiamyloid therapies; and (3) deepening our understanding of the pathogenesis of Alzheimer disease (AD). Another reason for . . . [Full Text of this Article]

AUTHOR INFORMATION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Assessment of β-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography With Carbon 11–Labeled Pittsburgh Compound B
Ville Leinonen, Irina Alafuzoff, Sargo Aalto, Timo Suotunen, Sakari Savolainen, Kjell Någren, Tero Tapiola, Tuula Pirttilä, Jaakko Rinne, Juha E. Jääskeläinen, Hilkka Soininen, and Juha O. Rinne
Arch Neurol. 2008;65(10):1304-1309.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease
Nelissen et al.
JNM 2009;50:1251-1259.
ABSTRACT | FULL TEXT